Related Experiment Video
Updated: Mar 25, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
Pathophysiology and management of cardiovascular disease in patients with HIV
Eric Nou1, Janet Lo1, Colleen Hadigan2
1Program in Nutritional Metabolism, Massachusetts General Hospital, Boston, MA, USA.
Insights
People with HIV face higher cardiovascular disease risks due to traditional factors and immune activation. Modern antiretroviral therapy can minimize myocardial infarction risk by suppressing the virus and reducing inflammation.
Area of Science:
- Cardiology
- Infectious Diseases
- Immunology
Background:
- Individuals with HIV exhibit elevated cardiovascular disease (CVD) risk, particularly coronary heart disease, compared to HIV-negative populations.
- Increased prevalence of traditional CVD risk factors and persistent immune activation are noted in people living with HIV (PLWH).
- Older antiretroviral therapy (ART) regimens were linked to higher CVD risk, likely due to metabolic side effects.
Purpose of the Study:
- To examine the impact of modern antiretroviral therapy (ART) on cardiovascular disease risk in people with HIV (PLWH).
- To understand the role of persistent immune activation in accelerated atherosclerosis despite ART.
- To explore potential additional cardiovascular protection strategies for PLWH.
Main Methods:
- Review of existing studies on HIV and cardiovascular disease.
- Analysis of the effects of modern versus older antiretroviral regimens.
- Investigation of immune activation markers and their correlation with atherosclerosis.
Main Results:
- Modern ART, when used early and continuously, appears to minimize myocardial infarction risk.
- Viral suppression and decreased immune activation are key benefits of modern ART regimens.
- Persistent immune activation in PLWH may contribute to accelerated atherosclerosis and vulnerable coronary lesions.
Conclusions:
- Early and continuous modern ART is crucial for reducing cardiovascular risk in PLWH.
- Addressing persistent inflammation through targeted treatments may offer additional cardiovascular protection.
- Comprehensive management of traditional and non-traditional risk factors is essential for cardiovascular health in PLWH.
Abstract:
Results from several studies have suggested that people with HIV have an increased risk of cardiovascular disease, especially coronary heart disease, compared with people not infected with HIV. People living with HIV have an increased prevalence of traditional cardiovascular disease risk factors, and HIV-specific mechanisms such as immune activation. Although older, more metabolically harmful antiretroviral regimens probably contributed to the risk of cardiovascular disease, new data suggest that early and continuous use of modern regimens, which might have fewer metabolic effects, minimises the risk of myocardial infarction by maintaining viral suppression and decreasing immune activation. Even with antiretroviral therapy, however, immune activation persists in people with HIV and could contribute to accelerated atherosclerosis, especially of coronary lesions that are susceptible to rupture. Therefore, treatments that safely reduce inflammation in people with HIV could provide additional cardiovascular protection alongside treatment of both traditional and non-traditional risk factors.
Related Concept Videos
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Cardiomyopathy V: Interprofessional Care
Myocarditis III: Medical Management
Heart Failure V: Medical Management
Rheumatic Heart Disease IV: Nursing Management

